X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TH1902 (sudocetaxel zendusortide) is an investigational, first-in-class peptide-drug conjugate (PDC) that targets SORT1. It is being developed for the treatment of high-grade serous ovarian cancer, including high-grade fallopian tube cancer, or endometrioid cancer.
Lead Product(s): Sudocetaxel Zendusortide
Therapeutic Area: Oncology Product Name: TH1902
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Trogarzo (ibalizumab-uiyk) is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. It is being evaluated for the treatment of adults with multidrug-resistant HIV-1 infection.
Lead Product(s): Iibalizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
TH1902 (sudocetaxel zendusortide) is an investigational, first-in-class peptide-drug conjugate (PDC) that targets SORT1. It is being developed for the treatment of high-grade serous ovarian cancer, including high-grade fallopian tube cancer, or endometrioid cancer.
Lead Product(s): Sudocetaxel Zendusortide
Therapeutic Area: Oncology Product Name: TH1902
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Egrifta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Lead Product(s): Tesamorelin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Egrifta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
Trogarzo (ibalizumab-uiyk) is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Its intramuscular dosage regimen is under phase 3 clinical development for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Lead Product(s): Ibalizumab-uiyk
Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Trogarzo (ibalizumab-uiyk) is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor which is appproved as 90-second intravenous (IV) push loading dose for the treatment of HIV-1 infection.
Lead Product(s): Iibalizumab-uiyk
Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
Trogarzo (ibalizumab-uiyk) is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. In the United States, Trogarzo, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Lead Product(s): Ibalizumab-uiyk
Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
Trogarzo (ibalizumab-uiyk) is a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their current antiretroviral regimen.
Lead Product(s): Iibalizumab-uiyk
Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
TH1902 (sudocetaxel zendusortide) is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin (SORT1) receptor and expedites the internalization and delivery of a cytotoxic payload directly into cancer cells.
Lead Product(s): Sudocetaxel Zendusortide
Therapeutic Area: Oncology Product Name: TH1902
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
